Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Biocon Ltd. has launched its drug-device combination for diabetes and obesity, Diavorin and Vobexoryn respectively, in the Netherlands via Pharmamedic BV.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Dec 12 (Reuters) - Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Get the latest stock market and healthcare sector updates, top gainers and losers, and key regulatory news impacting investments.